• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Top Cannabis Appointments You Should Know About: Aurora's New CFO And Other Changes

    2/20/24 9:11:11 AM ET
    $ACB
    $BGXX
    $BMY
    $CL
    Medicinal Chemicals and Botanical Products
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ACB alert in real time by email

    New Cannabis CEOs, CFOs And Other Appointments

    Canadian medical cannabis giant Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB) announced on Tuesday that Simona King, a former executive of Bristol Myers-Squibb (NYSE:BMY) has been named the company's new CFO, replacing Glen Ibbott at the new role.

    Aurora simultaneously announced the completion of its consolidation of the common shares of the company on a 10 to 1 basis. The common shares will begin trading on a post-consolidation basis on the NASDAQ Capital Market and the Toronto Stock Exchange (TSX) under the symbol “ACB” at the opening of trading on Tuesday.

    Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBF) (FSE: 6CQ) kicked off the month by announcing the promotion of Greg Butler to the position of president. Butler, who joined the Chicago-based company in 2020 as CCO, agreed to oversee all aspects of the company's operations, including production, retail operations, marketing and sales, corporate planning and investor relations.

    Last week, The Hempshire Group, Inc. (TSXV:HMPG) said CEO and Director Alex Shegelman, has retired as CEO, while remaining on the board of directors of the Calgary, Alberta-based company. Tom Shuman, a CPG sales and marketing veteran, agreed to assume Shegelman's role as CEO, while Kevin Bautier, who has been working with Hampshire in accounting since its beginnings in 2019, has agreed to lead the company's finance department, as new CFO.

    Vancouver-based cannabis company Rubicon Organics Inc. (TSXV:ROMJ) (OTCQX: ROMJF) appointed Margaret Brodie as its new CEO. Brodie has been serving as interim CEO and CFO for over a year. The company also named Janis Risbin as CFO and corporate secretary. Serving first as director and VP, Risbin has been instrumental in the success of the company from the early start-up of the Canadian business.

    Los Angeles-based STIIIZY INC. named Isaac Kim its new CFO earlier this month. Kim brings extensive corporate finance and C-suite experience as a seasoned financial leader who steered high-growth companies.

    Another California-based cannabis operator Lowell Farms Inc. (CSE:LOWL) (OTCQX:LOWLF), appointed Jamie Schniedwind as its new director of finance. Schniedwind brings finance and accounting expertise to the company as the new CFO, replacing Tessa O'Dowd, who previously held the role of interim CFO.

    AgriCann Solutions Corp.'s Dome Duong recently opted to resign as the company's CFO and as a director.

    Saskatoon, Saskatchewan-based ZYUS Life Sciences Corporation (TSXV:ZYUS), a sciences company conducting scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, appointed Hance Clarke, MD, PhD, FRCPC to the company's Clinical Advisory Committee.

    See also: Who’s Who In Cannabis: January Executive Changes You Should Know About

    Cannabis Board Changes

    In the meantime, several cannabis companies made changes to their respective boards of directors.

    The Colorado-based medical cannabis pioneer Charlotte’s Web Holdings, Inc. (OTCQX:CWBHF) (TSX:CWEB) tapped Matthew E. McCarthy, the former CEO of Ben & Jerry’s Homemade, to serve on its board earlier this month. The company said McCarthy is expected to bring a "unique blend of commercial acumen and deep commitment to social impact within the consumer-packaged goods (CPG) and natural products industries."

    Bright Green Corporation (NASDAQ:BGXX), a company that was selected and approved by the US government to legally grow, manufacture, and sell cannabis and cannabis-related products for research, pharmaceutical applications and affiliated exports, said its CEO Groovy Singh opted to join the company's board. Simultaneously, co-founder Lynn Stockwell was named the new chair of the board, replacing Terry Rafih, who resigned.

    Glass House Brands Inc. (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) recently said John Pérez has stepped down from the board, due to increasing commitments with his current employer.

    Christina Lake Cannabis Corp. (CSE:CLC) (OTCQB:CLCFF) (FRANKFURT: CLB) re-elected all director nominees, including Joel Dumaresq, Salvatore Milia, Nicco Dehaan, Mervin Boychuk, Gil Playford and James McMillan to its board ahead of completing a $3 million deal to acquire outdoor cultivation facilities in Midway, British Columbia, related harvesting and manufacturing equipment, and approximately 19,000 kg. of cannabis biomass.

    The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

    Get your tickets now on bzcannabis.com, Prices will increase soon! 

    Get the next $ACB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACB
    $BGXX
    $BMY
    $CL

    CompanyDatePrice TargetRatingAnalyst
    Aurora Cannabis Inc.
    $ACB
    1/27/2026Buy
    Canaccord Genuity
    Colgate-Palmolive Company
    $CL
    1/13/2026$86.00Underweight → Equal Weight
    Wells Fargo
    Colgate-Palmolive Company
    $CL
    1/7/2026$88.00Neutral → Overweight
    Piper Sandler
    Bristol-Myers Squibb Company
    $BMY
    1/7/2026$65.00Neutral → Buy
    UBS
    Bristol-Myers Squibb Company
    $BMY
    12/15/2025$61.00Neutral → Buy
    BofA Securities
    Bristol-Myers Squibb Company
    $BMY
    12/12/2025$62.00Neutral → Buy
    Guggenheim
    Colgate-Palmolive Company
    $CL
    12/11/2025Buy → Hold
    Argus
    Colgate-Palmolive Company
    $CL
    12/9/2025$88.00Sector Perform → Outperform
    RBC Capital Mkts
    More analyst ratings

    $ACB
    $BGXX
    $BMY
    $CL
    SEC Filings

    View All

    SEC Form 6-K filed by Aurora Cannabis Inc.

    6-K - AURORA CANNABIS INC (0001683541) (Filer)

    2/12/26 4:26:03 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Core Laboratories Inc.

    SCHEDULE 13G/A - Core Laboratories Inc. /DE/ (0001958086) (Subject)

    2/12/26 4:19:45 PM ET
    $CLB
    Oilfield Services/Equipment
    Energy

    SEC Form 10-K filed by Bristol-Myers Squibb Company

    10-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

    2/11/26 11:35:11 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACB
    $BGXX
    $BMY
    $CL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

    For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

    9/26/24 6:42:20 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 14, 2024 - FDA Roundup: June 14, 2024

    For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

    6/14/24 3:54:45 PM ET
    $MMSI
    $BMY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    March 8, 2024 - FDA Roundup: March 8, 2024

    For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and

    3/8/24 3:26:46 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACB
    $BGXX
    $BMY
    $CL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    COO, Eur., APac, Afr Eur, Skin Tsourapas Panagiotis sold $4,778,436 worth of shares (50,000 units at $95.57) and exercised 50,000 shares at a strike of $76.41 (SEC Form 4)

    4 - COLGATE PALMOLIVE CO (0000021665) (Issuer)

    2/13/26 4:25:19 PM ET
    $CL
    Package Goods/Cosmetics
    Consumer Discretionary

    Chief Growth Officer Hazlin John exercised 20,989 shares at a strike of $76.41 and sold $1,978,211 worth of shares (20,989 units at $94.25) (SEC Form 4)

    4 - COLGATE PALMOLIVE CO (0000021665) (Issuer)

    2/12/26 4:08:05 PM ET
    $CL
    Package Goods/Cosmetics
    Consumer Discretionary

    EVP and Controller Malcolm Gregory exercised 12,747 shares at a strike of $76.41 and sold $1,209,822 worth of shares (12,747 units at $94.91) (SEC Form 4)

    4 - COLGATE PALMOLIVE CO (0000021665) (Issuer)

    2/10/26 4:21:26 PM ET
    $CL
    Package Goods/Cosmetics
    Consumer Discretionary

    $ACB
    $BGXX
    $BMY
    $CL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    4/29/25 6:14:13 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Boerner Christopher S. bought $110,096 worth of shares (2,000 units at $55.05), increasing direct ownership by 2% to 104,626 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    2/21/25 7:09:34 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $100,000 worth of shares (1,823 units at $54.84), increasing direct ownership by 3% to 63,932 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    2/19/25 7:19:54 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACB
    $BGXX
    $BMY
    $CL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aurora to Ring the Nasdaq Closing Bell on Wednesday, February 18, 2026, Reinforcing Strategic Focus on Global Medical Cannabis

                                                                                  NASDAQ | TSX: ACB EDMONTON, AB, Feb. 12, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, announces the company will ring the Nasdaq closing bell on Wednesday, February 18, 2026, at the Nasdaq MarketSite in New York's Times Square. The ceremony will be led by Aurora's CEO and Executive Chairman, Miguel Martin, alongside a representative of the company's Board of Directors, executive leadership team and other employees. This e

    2/12/26 4:05:00 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

    The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua

    2/11/26 5:31:00 PM ET
    $ABBV
    $AVBP
    $BDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Aurora Advances Global Medical Growth Strategy with Portfolio Expansion in Australia & New Zealand

    NASDAQ | TSX: ACB Launch reinforces Aurora's leadership position across key international markets  EDMONTON, AB, Feb. 11, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, is expanding its Aurora® medical portfolio in Australia and New Zealand, delivering patients and prescribers enhanced choice, reliable quality, and easier access to science-backed products. The expansion underscores the company's ongoing dedication to meeting the unique needs of patients and healthcare professionals in the region, reflecting Aurora's strategic focus on long-term global growth.

    2/11/26 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    $BGXX
    $BMY
    $CL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Aurora Cannabis

    Canaccord Genuity initiated coverage of Aurora Cannabis with a rating of Buy

    1/27/26 9:29:20 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Colgate-Palmolive upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Colgate-Palmolive from Underweight to Equal Weight and set a new price target of $86.00

    1/13/26 8:40:58 AM ET
    $CL
    Package Goods/Cosmetics
    Consumer Discretionary

    Colgate-Palmolive upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Colgate-Palmolive from Neutral to Overweight and set a new price target of $88.00

    1/7/26 8:42:57 AM ET
    $CL
    Package Goods/Cosmetics
    Consumer Discretionary

    $ACB
    $BGXX
    $BMY
    $CL
    Leadership Updates

    Live Leadership Updates

    View All

    Aurora Names Seasoned Global CPG Executive to Lead Australia and New Zealand

    NASDAQ | TSX: ACB EDMONTON, AB, Dec. 8, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, announces Kerry Miller, a 35-year consumer packaged goods executive, as Managing Director for Australia and New Zealand, effective January 15, 2026. Kerry will be instrumental in driving growth in these key markets, drawing on decades of global experience in fast moving, regulated industries. "I'm excited to join Aurora at an inflection point in the company's global leadership and to work alongside a team dedicated

    12/8/25 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Announces Distribution Partnership with Leafio Australia

    The collaboration will improve medical cannabis access and better serve patients across Australia NASDAQ | TSX: ACB EDMONTON, AB, Dec. 2, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, today announced the company's wholly owned subsidiary, MedReleaf Australia, has entered into a distribution partnership with Leafio, the wholesale distribution arm of Montu Australia. This strategic partnership will expand patient access to trusted, safe, and effective medical cannabis across Australia, while supporting healthcare professionals with educational resources. Leafio will serve as a wholesaler of Aurora's leading portfoli

    12/2/25 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Rubicon Organics Announces Appointment of Glen Ibbott as CFO

    VANCOUVER, British Columbia, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV:ROMJ) (OTCQX:ROMJF) ("Rubicon Organics", "Rubicon", or the "Company"), a licensed producer focused on cultivating and selling organic certified and premium cannabis products, today announced the appointment of Glen Ibbott, a cannabis industry veteran and former Chief Financial Officer of Aurora Cannabis Inc. (TSX:ACB, NASDAQ:ACB) as its Chief Financial Officer and Corporate Secretary. "Over the past six months, Glen has demonstrated exceptional leadership, deep industry expertise, and a strong alignment with our values. His strategic insight and financial acumen have already made a significant impac

    11/12/25 8:00:00 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    $BGXX
    $BMY
    $CL
    Financials

    Live finance-specific insights

    View All

    Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025

    Bristol Myers Squibb (NYSE:BMY) today reported fourth quarter and full-year 2025 financial results. Visit the company's Investor Relations website at http://investor.bms.com to view the detailed fourth quarter and full-year 2025 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, February 5, 2026, which is accessible here. Company executives will review financial results with the investment community during the call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb:

    2/5/26 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CORE LAB REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS

    FOURTH QUARTER REVENUE OF $138.3 MILLION, UP 3% SEQUENTIALLY AND UP 7% YEAR-OVER-YEARFOURTH QUARTER OPERATING INCOME OF $15.8 MILLION; EX-ITEMS, $15.7 MILLION, DOWN 5% SEQUENTIALLY AND FLAT YEAR-OVER-YEARFOURTH QUARTER OPERATING MARGINS, EX-ITEMS, OF OVER 11%, DOWN 100 BASIS POINTS SEQUENTIALLY AND 80 BASIS POINTS YEAR-OVER-YEARFOURTH QUARTER GAAP EPS OF $0.15; EX-ITEMS, $0.21, DOWN 4% SEQUENTIALLY AND YEAR-OVER-YEARFOURTH QUARTER FREE CASH FLOW OF $5.1 MILLIONNET DEBT REDUCED BY $1.2 MILLION; LEVERAGE RATIO IMPROVED TO 1.09COMPANY REPURCHASED 363,207 SHARES OF COMMON STOCK, FOR $5.7 MILLION AGGREGATE PURCHASE PRICECOMPANY ANNOUNCES Q1 2026 QUARTERLY DIVIDENDFULL YEAR REVENUE OF $526.5 MILLI

    2/4/26 5:15:00 PM ET
    $CLB
    Oilfield Services/Equipment
    Energy

    Aurora Cannabis Announces Fiscal 2026 Third Quarter Results

    NASDAQ | TSX: ACB Expands YoY Total Net Revenue1 by 7% to $94.2 million, with Global Medical Cannabis Net Revenue1 Increasing by 12% to a Record $76.2 millionDelivers Adjusted EBITDA1 of $18.5 million and Adjusted Net Income1 of $7.2 millionGenerates Free Cash Flow1 of $15.5 million Maintains Strong Balance Sheet with $154.4 million of Cash2 and Short-Term Investments, and a Debt-Free Cannabis Business2EDMONTON, AB, Feb. 4, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the third quarter 2026 period ending December 31, 2025.

    2/4/26 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    $BGXX
    $BMY
    $CL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Colgate-Palmolive Company (Amendment)

    SC 13G/A - COLGATE PALMOLIVE CO (0000021665) (Subject)

    2/13/24 5:02:36 PM ET
    $CL
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form SC 13D/A filed by Bright Green Corporation (Amendment)

    SC 13D/A - Bright Green Corp (0001886799) (Subject)

    9/6/23 5:19:19 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D filed by Bright Green Corporation

    SC 13D - Bright Green Corp (0001886799) (Subject)

    6/15/23 4:30:21 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care